AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03955510 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Delayed time eating
Description: Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have delayed time eating with alcohol , the second time the will have this intervention without alcohol.
Study NCT03955510 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sigmoidoscopy
Description: Subjects will undergo unprepped sigmoidoscopy to collect tissue and stool sample at each intervention visits (visit 2, 3, 4, and 5). Flexible sigmoidoscopy will not require any colon cleansing and it will be very limited to the most distal (closest to the end of the anus) 20 centimeters (approximately 8 inches) of the colon and thus will be far less uncomfortable than the routine flexible sigmoidoscopy.
Study NCT03955510 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optional 24h circadian assessment in the Biological Rhythms lab
Description: Subjects may choose to participate in the 24 hour circadian assessment in the Biological Rhythms Research Lab. During this assessment, a saliva sample will be taken every hour, a mouth swab will be done every 2 hours, and rectal swab will be done twice (every 12 hours). Subjects will be kept awake in dim light on a recliner chair. Subjects can watch a television with dimmed light. Subjects will be provided with food and drink during the assessment.~If subjects choose this intervention they will be asked to complete 4 assessment during the course of the study period.
Study NCT03955510 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Alcohol
Description: Moderate alcohol drinking means 0.5 g/kg alcohol daily, which will be not more than 2 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 2 alcohol intervention weeks. The order of conditions will be random.
Study NCT04356937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)
Study NCT04356937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)
Study NCT00570401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Study NCT01081613 — intervention group
Intervention type: OTHER
Intervention: 89Zr-bevacizumab PET imaging
Description: injection 89Zr-bevacizumab and 89 Zr-bevacizumab PET scan
Study NCT00003677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolastatin 10
Description: IV bolus once every 21 days.
Study NCT02244671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fat, PRP, botulinum toxin
Description: fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
Study NCT02244671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin
Description: botulinum toxin used to immobilize extra-ocular muscles prior to fat injection.
Study NCT02244671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRP
Description: autologous PRP is prepared with a dedicated centrifuge at the time of fat harvesting
Study NCT01811537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Chordae
Study NCT03502499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half-normal saline
Description: Use of half-normal saline as an irrigant for open-irrigated ablation catheters
Study NCT03502499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Use of normal saline as an irrigant for open-irrigated ablation catheters
Study NCT03166787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charcoal hookah
Description: The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with either charcoal for 30 min each.
Study NCT03166787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-coal hookah
Description: The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with electrically (Global First e-coal, ) for 30 min each.
Study NCT03166787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette
Description: The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young cigarette smokers smoke 2 cigarettes down to the stub over 30 min (to simulate real-world use).
Study NCT03166787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Monoxide inhalation
Description: A subset (n=8) of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling 0.3 CO gas from a Douglas bag.
Study NCT03166787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room Air inhalation
Description: A subset 8 of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling room air from a Douglas bag.
Study NCT03166787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin C
Description: in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with either i.v. vitamin C .
Study NCT03166787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with one dose of oral tadalafil.
Study NCT03026946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alitretinoin
Description: Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
Study NCT03026946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporin A
Description: Oral cyclosporine A start dose 5 mg/kg/day (split in 2 doses), decreasing the dose after 8 weeks to 3 - 3.5 mg/kg/day (split in 2 doses). The treatment period is 24 weeks.
Study NCT05007119 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mckenzie Extension Protocol
Description: Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence~Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing
Study NCT05007119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mckenzie Extension Protocol
Description: Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence~Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing
Study NCT05007119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cupping
Description: Cupping with blood letting
Study NCT00467519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)
Description: 0.5 mL, IM
Study NCT03796377 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: St Johns Wort Extract
Description: 20 mg rivaroxaban after supplementation with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.
Study NCT03796377 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban
Description: 20 mg rivaroxaban.
Study NCT02512731 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal Doppler Monitor
Description: Esophageal doppler monitoring (EDM) is a minimally invasive means of continuously measuring the cardiac output from the pattern of blood flow in the descending thoracic aorta.
Study NCT00704899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Structured exercise regimen
Study NCT00704899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitryptiline
Description: Amitryptiline 25mg once daily
Study NCT00467519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)
Description: 0.5 mL, IM
Study NCT01367015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Feeding
Description: Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
Study NCT01367015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late Feeding
Description: Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
Study NCT01516138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIK
Description: Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
Study NCT01516138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
Study NCT02823353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 200mg/day
Study NCT02767336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Glucose Monitoring System.
Description: In vitro diagnostic medical device
Study NCT02823353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: UDCA 13-15mg/kg/day
Study NCT02823353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Description: UDCA 13-15mg/kg/day
Study NCT02657044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMR
Study NCT02657044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESD
Study NCT05355285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glucose Clamp
Description: Subjects receive variable rates of glucose or insulin infusions to adjust and maintain desired plasma glucose or insulin levels.
Study NCT00316017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline/6% Dextran-70 (HSD)
Description: 250 cc dose given as a one-time intravenous (IV) bolus in the pre-hospital setting.
Study NCT00316017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HS)
Description: 250 cc dose given as a one-time IV bolus in the pre-hospital setting.
Study NCT02115100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: procedure
Description: Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only
Study NCT03973580 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attentional Bias Modification (ABM) task
Description: Participants will be presented with a fixation cross (500ms) followed by a pair of identity-matched, angry-neutral faces (1000ms). The pair presentation is replaced by a single arrow-probe (1000ms) in the position of the neural face. Inter-trial intervals (ITI) are 500ms. Participants indicate arrow direction (left or right) by pressing one of two buttons as quickly as possible. By responding to the probe that always replaces the neutral face, participants learn to attend to the non-threat cues and away from threat cues. There are 120 trials of angry-neutral faces in total, and 40 other catch trials with neutral-neutral faces.
Study NCT03973580 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control task
Description: The control task is identical with the ABM task, except that in the 120 angry-neutral trials, the arrow-probe replaces the angry face and the neutral face with equal probabilities (60 trials each).
Study NCT01483638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: 5 mg BID taken orally with food continuously on Day 1 of the study. One cycle corresponds to 28 days.
Study NCT01483638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: will be administered orally with the same schedule of axitinib
Study NCT04327921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer navigation social support for smoking cessation
Description: Standard guidelines will be used for brief advice for smoking cessation based on the 5A's. Also, motivational interviewing/guidance will also be used to determine whether enhanced treatment (using a Peer Navigator to navigate smoking cessation, obtain medication and treatment, improve adherence to treatment, and provide social support for quitting) will increase participant's quit attempts and smoking cessation rates.
Study NCT04327921 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Condition
Description: Standard guidelines will be used for brief advice for smoking cessation based on the 5A's.
Study NCT01394289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lolium allergen extract
Description: This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
Study NCT02552108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural experiments for intolerance of uncertainty (BE-IU)
Study NCT04500444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes.
Study NCT04500444 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: exercise training
Description: An aerobic exercise program with blood flow restriction will be applied 4 times a week for a total of 6 weeks. The aerobic exercise training consists of a warm up period for 5 minutes, walking on treadmill at 4 km per hour speed for 20 minutes and cooling down for another 5 minutes.
Study NCT04622566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib, Pembrolizumab
Description: After enrollment, patients receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 6 weeks; Lenvatinib 20mg orally once daily for 6 weeks. Patients conduct surgery within 1-4 weeks after the last dose of Pembrolizumab and Lenvatinib. After complete surgery, Pembrolizumab will be as adjuvant treatment for up to 15 cycles, 200mg IV on day 1 of every 21 day-cycles.
Study NCT01705938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP-333
Study NCT03830268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: No MCT intake with breakfast, no lunch
Description: Water given with a regular standardize breakfast and water given at noon without lunch.
Study NCT03830268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: No MCT intake with lunch, no breakfast
Description: Water given in the beginning of the metabolic study day without breakfast and water given at noon with a regular standardize lunch.
Study NCT03830268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10g of Betaquik
Description: BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.
Study NCT03830268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10g of Betaquik with low-carbs breakfast
Description: BQ10 given with a low-carbs standardize breakfast and BQ10 given at noon without lunch.
Study NCT03830268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20g of Betaquik
Description: BQ20 given with a regular standardize breakfast and BQ20 given at noon without lunch.
Study NCT03830268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10g of Betaquik with lunch, no breakfast
Description: BQ10 given in the beginning of the metabolic study day without breakfast and BQ10 given at noon with a regular standardize lunch.
Study NCT02198846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulin pump
Description: stop any antihyperglycemic medication and convert to insulin pump
Study NCT00316017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: 250 cc dose given as a one-time IV bolus in the pre-hospital setting.
Study NCT02198846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: intensification of conventional treatment by adding oral antihyperglycemic agents or subcutaneous insulin (once / twice/ multiple injection)
Study NCT02144870 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habit Reversal Training
Description: awareness training, competing response training
Study NCT02144870 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resources activation
Study NCT02523430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional therapy
Description: nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Study NCT02523430 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: interventional therapy
Description: nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Study NCT02557399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duac® fixed dose combination gel
Description: Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.
Study NCT02557399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADA 0.1% gel
Description: ADA 0.1% gel containing 0.1% of adapalene.
Study NCT02557399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLDM 1% gel
Description: CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).
Study NCT00924846 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency oscillatory ventilation
Description: Mechanical ventilation as high frequency oscillatory ventilation for 8h periods
Study NCT00596271 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC51
Study NCT00596271 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HAVRIX
Study NCT00596271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00577317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management of Therapy Complications
Description: Receive standard home maintenance therapy and perform self-manual lymphatic drainage
Study NCT00565487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Tarceva
Description: Capecitabine is a self-administered (oral) medication \& will be dose escalated and administered in four dose levels: Level I - 600 mg/m2 bid; Level II - 700 mg/m2 bid; Level III - 825 mg/m2 bid; Level IV - 925 mg/m2 bid. Tarceva will be self-administered(orally) in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single agent Tarceva 100 mg/day. Treatment of Capecitabine \& Tarceva is continued daily until the completeness of the radiation or toxicity.
Study NCT04157400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative Parameter Testing
Description: Step 1: Recording and stimulation of spinal potentials during insertion of epidural spinal stimulator paddle~Once the epidural paddle is placed, study procedures will begin by connecting the terminals of the paddle to an electrophysiological recording device for signal amplification and filtering. Using this recording setup, motor evoked potential (MEP) and somatosensory evoked potential (SSEP) protocols will be performed to determine motor and sensory thresholds, respectively. Next, the surgical procedure will resume and after the implantable pulse generator (IPG) has been placed, study procedures will begin again and include activation of both low-frequency tonic stimulation (LFTS) and high-frequency burst stimulation (HFBS) patterns from the inserted paddle while recording EMG signals.